ncRNA basic information
ncRNA ID:
MIMAT0000242
ncRNA Database:
miRBase
ncRNA Name:
miR-129-5p
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
qRT-PCR
ncRNA Target Gene:
SOX2
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00997 (APRD00185, DB05331, DB05847)
Drug Name:
Adriamycin
Drug Method:
By qRT-PCR assay, we revealed that the expression of miR-129-5p was significantly decreased in breast cancer tissues and Adriamycin-resistant breast cancer cells (MDA-MB-231/ADR, MCF-7/ADR). CCK-8, colony formation, wound healing, Transwell invasion, and flow cytometric profiles were examined to determine the influence of miR-129-5p on Adriamycin-resistant breast cancer in vitro. The upregulation of miR-129-5p decreased the IC50 concentration of Adriamycin and invasion and promoted the apoptosis of MDA-MB-231/ADR cells in the presence of Adriamycin, whereas the upregulation of SOX2 reversed these effects. A luciferase reporter assay confirmed the binding of miR-129-5p to the 3'UTR of SOX2. Collectively, it was suggested that miR-129-5p suppresses Adriamycin resistance in breast cancer by directly targeting SOX2.
Drug Response:
sensitive
Cancer basic information
Cancer:
breast cancer
Tissue/Cell:
tissue and cell line (MDA-MB-231, MCF-7,MDA-MB-231/ADR,MCF-7/ADR)
Other information
Title:
microRNA-129-5p suppresses Adriamycin resistance in breast cancer by targeting SOX2.
Journal:
Arch Biochem Biophys
Published:
2018
PubMed ID:
29802821